Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20thNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company, today announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Eyenovia stockholders entitled to vote at the Company’s 2025 Special ...

Reverse Stock Split Proposal - The company is proposing a reverse stock split at a ratio between 1:40 and 1:80 to regain compliance with Nasdaq's Minimum Bid Price Requirement [1][6] - The reverse stock split aims to maintain the company's Nasdaq Capital Market listing, which provides increased visibility, stock liquidity, and access to capital [1] - Two leading proxy advisory firms, ISS and Glass Lewis, have recommended that stockholders vote in favor of the reverse stock split [6] Special Meeting Details - The Special Meeting will be held virtually on January 21, 2025, at 10:00 a.m. Eastern Time [7] - Stockholders must pre-register by January 20, 2025, at 11:59 p.m. Eastern Time to attend the meeting [7] - Stockholders of record as of December 9, 2024, are eligible to vote [7] Additional Proposals - Proposal to amend the 2018 Omnibus Stock Incentive Plan to reserve an additional 350,000 shares of common stock [9] - Proposal to approve the potential issuance of up to 73,029,273 shares upon the exercise of certain outstanding warrants [9] - Proposal to authorize an adjournment of the Special Meeting if necessary to solicit additional proxies [9] Company Overview - Eyenovia is an ophthalmic technology company developing the Optejet topical ophthalmic medication dispensing platform [8] - The Optejet platform targets both home use for ocular lubrication and chronic front-of-the-eye diseases [8] - The platform offers ease of use, enhanced safety and tolerability, and potential for improved treatment compliance [8]

Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60%NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has engaged Chardan as its financial advisor in connection with its evaluation of strategic alterna ...

Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic alternatives to maximize stakeholder value NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today provided an update on its ongoing restructuring efforts. The Company announced today that Avenue Capital Management L.P. has agreed to support a potential restruc ...

Eyenovia, Inc. (EYEN) announced the decision to terminate a phase III study evaluating its investigational drug-device product, MicroPine, as a potential treatment for pediatric progressive myopia. MicroPine is EYEN’s proprietary drug-device combination of low-dose atropine administered using the company’s Optejet dispensing platform.The decision was taken after an independent Data Review Committee (DRC) determined that the phase III CHAPERONE study of MicroPine was unlikely to meet its primary endpoint of ...

On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company’s Optejet dispensing platform pediatric progressive myopia.Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long.The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting its primary endpoint of ...

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and evaluate next steps for the program NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that a review of the CHAPERONE data by an independent Data Review Committee (DRC) found that the trial is not meeting its primary endpoint of a less than 0 ...

Eyenovia, Inc. (NASDAQ:EYEN) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Participants Matthew Caufield - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Lachlan Hanbury-Brown - William Blair Kemp Dolliver - Brookline Capital Markets Len Yaffe - Stoc Doc Partners Operator Greetings and welcome to Eyenovia's Third Quarter 2024 Earnings Call. At this time, all participants are in a liste ...

Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.18, delivering a surprise of -5.88%.Over the last four quarters, the company has surpassed ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. (Exact name of R ...